Using Autologous Platelet Rich Plasma (PRP) Gel to Treat Deep 2nd and 3rd Degree Burns
This trial is active, not recruiting.
|Treatments||magellan®, placebo saline gel and usual and customary standard of care|
|Collaborator||United States Department of Defense|
|Start date||April 2013|
|End date||May 2017|
|Trial size||42 participants|
|Trial identifier||NCT01843686, ART-11-004|
This study will demonstrate the safety of the application of autologous platelet rich plasma (PRP) gel following excision and autologous skin grafting of acute deep 2nd and 3rd degree burns. The study will be a randomized, double-blinded controlled safety study. Investigators expect that the PRP will deliver improved hemostasis and growth factors at the wound site thus increasing the effectiveness of treatment at the wound site. This will lead to rapid production and delivery of an autologous therapy that should minimize additional morbidity to the patient.
|United States||No locations recruiting|
|Other countries||No locations recruiting|
|Sacramento, CA||University of California, Davis, Division of Burn Surgery||no longer recruiting|
|Washington, DC||Medstar Health Research Institute||no longer recruiting|
|Salt Lake City, UT||University of Utah Hospital||no longer recruiting|
|Intervention model||parallel assignment|
|Masking||care provider, investigator|
Demonstrate the safety of application of autologous platelet rich plasma (PRP) gel following excision of an acute deep 2nd and 3rd degree burn.
time frame: 12 Months
Assessment of a composite of wound healing measurements
time frame: 12 Months
All participants from 18 years up to 86 years old.
Inclusion Criteria: - Written informed consent obtained either the subject or the subject's legally acceptable representative prior to screening activities - Male or female age ≥ 18 and ≤ 86 years of age - Total burn wound measuring ≤ 20% TBSA to include a deep partial thickness/full thickness area requiring surgical excision and autologous split thickness skin grafts - Hemoglobin HbA1c ≤7.5% (for patients with pre-existing diabetes mellitus) - Able and willing to comply with the procedures required by the protocol. Patients may be managed as either inpatient or outpatient. - If a female of childbearing potential, the subject must have a negative serum pregnancy test at screening - All participants, male and female, must use acceptable method(s) of birth control for the duration of the study - Female subjects must be of non-childbearing potential (defined as postmenopausal for at least 1 year or surgically sterile [bilateral tubal ligation, bilateral oophorectomy or hysterectomy]) or must be using adequate contraception (practicing one of the following methods of birth control): - Total abstinence from sexual intercourse (minimum of one complete menstrual cycle before study entry), - A partner who is physically unable to impregnate the subject (e.g., vasectomized) - Contraceptives (oral, parenteral, or transdermal) for 3 consecutive months prior to the patient's cell concentrate administration, - Intrauterine device (IUD)or, - Double-barrier method (condoms, sponge, diaphragm, or vaginal ring with spermicidal jellies or cream) Exclusion Criteria: - Conductive electrical burns and chemical burns - Digits, head, genitalia, palms of hands, soles of feet, and face are excluded as test sites - Burns that pose a risk to digits or limbs - Test area with infection as determined clinically by the investigator prior to surgery - Venous or arterial vascular disorder directly affecting a designated test area - Known immune deficiency disorder, either congenital or acquired - Chronically malnourished as determined clinically by the investigator prior to surgery (Investigators are responsible for determining subjects are chronically malnourished during the screening process. Investigators should take into consideration the following parameters: medical history and physical appearance, the subject's body mass index, and any significant laboratory findings) - Severe respiratory problems or concurrent head trauma at hospital admission, including inhalation injury requiring ventilatory support - Any chronic condition requiring the use of systemic corticosteroids 30 days prior to study entry and anytime during the course of the study - Any other acute or chronic concurrent medical condition(s) that in the investigator's opinion are a contraindication to skin grafting and study participation or limit the participant's life expectancy to < 6 months - Known or suspected hypersensitivity to bovine protein - Concurrent participation in another clinical trial in which an investigational agent is used. (Subjects must not have been enrolled in another clinical trial within 30 days of enrolling in this trial) - Females who are pregnant or nursing or intend to become pregnant during the duration of the study - Burn wounds that occur over joints - Patients with the following abnormal laboratory test levels: - Stage 4 or greater chronic kidney disease (eGFR < 30 mL/min) - Hemoglobin < 10 g/dL - Thrombocytopenia < 100,000 platelets/µL - Serum albumin level <2.5 g/dL or > 30 g/dL at time of screening
|Official title||Use of Autologous Platelet Rich Plasma (PRP) Gel as an Adjunct to the Treatment of Deep 2nd and 3rd Degree Burns|
|Description||The goal of this study is to demonstrate the safety of the application of autologous platelet rich plasma (PRP) gel following excision and autologous skin grafting of acute deep 2nd and 3rd degree burns. This treatment is intended to stimulate rapid healing and improve the outcome of standard of care treatments for burns common to active duty military personnel, and more broadly for treatment of all acute burns. The care is specific to excision and split thickness skin grafting in the context of this burn study. The study will enroll 42 patients receiving surgical management of acute 2nd and 3rd degree burns requiring excision and skin grafting. The patient's total body surface area burn injury should not exceed 20%. The study will be conducted for 12 months. This study will provide further information for the development of enhanced treatment of wound-deployable cellular therapy for advanced trauma care of burned warriors.|
Call for more information